These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 17233806

  • 21. Changes in baseline PSA levels in Japanese men from 1988 to 2003.
    Ohi M, Ito K, Yamamoto T, Miyakubo M, Takechi H, Kubota Y, Suzuki K.
    Urology; 2008 Jul; 72(1):95-8. PubMed ID: 18455775
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic.
    Price MM, Hamilton RJ, Robertson CN, Butts MC, Freedland SJ.
    Urology; 2008 May; 71(5):787-91. PubMed ID: 18267334
    [Abstract] [Full Text] [Related]

  • 28. Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening.
    Hutterer G, Perrotte P, Gallina A, Walz J, Jeldres C, Traumann M, Suardi N, Saad F, Bénard F, Valiquette L, McCormack M, Graefen M, Montorsi F, Karakiewicz PI.
    Eur J Cancer; 2007 May; 43(7):1180-7. PubMed ID: 17292604
    [Abstract] [Full Text] [Related]

  • 29. Hepatocyte growth factor and interleukin-6 in combination with prostate volume are possible prostate cancer tumor markers in patients with gray-zone PSA levels.
    Nishimura K, Arichi N, Tokugawa S, Yoshioka I, Namba Y, Kishikawa H, Takahara S, Ichikawa Y.
    Prostate Cancer Prostatic Dis; 2008 May; 11(3):258-63. PubMed ID: 17876341
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The potential role of prebiopsy magnetic resonance imaging combined with prostate-specific antigen density in the detection of prostate cancer.
    Kubota Y, Kamei S, Nakano M, Ehara H, Deguchi T, Tanaka O.
    Int J Urol; 2008 Apr; 15(4):322-6; discussion 327. PubMed ID: 18380820
    [Abstract] [Full Text] [Related]

  • 33. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M, Lam R, Strum S, Jennrich R, Johnson H, Trilling T.
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [Abstract] [Full Text] [Related]

  • 34. Fluctuating prostate-specific antigen levels in patients with initial negative biopsy: should we be reassured?
    Celhay O, de la Taille A, Salomon L, Doré B, Irani J.
    BJU Int; 2007 May; 99(5):1028-30. PubMed ID: 17324221
    [Abstract] [Full Text] [Related]

  • 35. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
    Jegu J, Tretarre B, Grosclaude P, Rebillard X, Bataille V, Malavaud B, Iborra F, Salama G, Rischmann P, Villers A.
    Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies.
    Stephan C, Kramer J, Meyer HA, Kristiansen G, Ziemer S, Deger S, Lein M, Loening SA, Jung K.
    BJU Int; 2007 Jun; 99(6):1427-31. PubMed ID: 17355366
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Reliability of self-report versus chart-based prostate cancer, PSA, DRE and urinary symptoms.
    Sayre EC, Bunting PS, Kopec JA.
    Can J Urol; 2009 Feb; 16(1):4463-71. PubMed ID: 19222884
    [Abstract] [Full Text] [Related]

  • 40. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
    Freedland SJ, Sun L, Kane CJ, Presti JC, Terris MK, Amling CL, Moul JW, Aronson WJ.
    BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.